Global Benign Prostate Hyperplasia Drugs Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Alpha Blocker
  • 1.4.3 5-Alpha Reductase Inhibitor
  • 1.4.4 Phosphodiesterase-5 Inhibitor
  • 1.4.5 Others
• 1.5 Market by Application
  • 1.5.1 Global Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2025)
  • 1.5.2 Hospital
  • 1.5.3 Clinic
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Benign Prostate Hyperplasia Drugs Market Size
• 2.2 Benign Prostate Hyperplasia Drugs Growth Trends by Regions
  • 2.2.1 Benign Prostate Hyperplasia Drugs Market Size by Regions (2019-2025)
  • 2.2.2 Benign Prostate Hyperplasia Drugs Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 Benign Prostate Hyperplasia Drugs Market Size by by Players
  • 3.1.1 Global Benign Prostate Hyperplasia Drugs Revenue by by Players (2014-2019)
  • 3.1.2 Global Benign Prostate Hyperplasia Drugs Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global Benign Prostate Hyperplasia Drugs Market Concentration Ratio (CR5 and HHI)
• 3.2 Benign Prostate Hyperplasia Drugs Key Players Head office and Area Served
• 3.3 Key Players Benign Prostate Hyperplasia Drugs Product/Solution/Service
• 3.4 Date of Enter into Benign Prostate Hyperplasia Drugs Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Benign Prostate Hyperplasia Drugs Market Size by Type (2014-2019)
• 4.2 Global Benign Prostate Hyperplasia Drugs Market Size by Application (2014-2019)

5 North America

• 5.1 North America Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
• 5.2 Benign Prostate Hyperplasia Drugs Key Players in North America
• 5.3 North America Benign Prostate Hyperplasia Drugs Market Size by Type
• 5.4 North America Benign Prostate Hyperplasia Drugs Market Size by Application

6 Europe

• 6.1 Europe Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
• 6.2 Benign Prostate Hyperplasia Drugs Key Players in Europe
• 6.3 Europe Benign Prostate Hyperplasia Drugs Market Size by Type
• 6.4 Europe Benign Prostate Hyperplasia Drugs Market Size by Application

7 China

• 7.1 China Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
• 7.2 Benign Prostate Hyperplasia Drugs Key Players in China
• 7.3 China Benign Prostate Hyperplasia Drugs Market Size by Type
• 7.4 China Benign Prostate Hyperplasia Drugs Market Size by Application

8 Japan

• 8.1 Japan Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
• 8.2 Benign Prostate Hyperplasia Drugs Key Players in Japan
• 8.3 Japan Benign Prostate Hyperplasia Drugs Market Size by Type
• 8.4 Japan Benign Prostate Hyperplasia Drugs Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
• 9.2 Benign Prostate Hyperplasia Drugs Key Players in Southeast Asia
• 9.3 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size by Type
• 9.4 Southeast Asia Benign Prostate Hyperplasia Drugs Market Size by Application

10 India

• 10.1 India Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
• 10.2 Benign Prostate Hyperplasia Drugs Key Players in India
• 10.3 India Benign Prostate Hyperplasia Drugs Market Size by Type
• 10.4 India Benign Prostate Hyperplasia Drugs Market Size by Application

11 Central & South America

• 11.1 Central & South America Benign Prostate Hyperplasia Drugs Market Size (2014-2019)
• 11.2 Benign Prostate Hyperplasia Drugs Key Players in Central & South America
• 11.3 Central & South America Benign Prostate Hyperplasia Drugs Market Size by Type
• 11.4 Central & South America Benign Prostate Hyperplasia Drugs Market Size by Application

12 International Players Profiles

• 12.1 Sanofi
  • 12.1.1 Sanofi Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Benign Prostate Hyperplasia Drugs Introduction
  • 12.1.4 Sanofi Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019))
  • 12.1.5 Sanofi Recent Development
• 12.2 Coloplast
  • 12.2.1 Coloplast Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Benign Prostate Hyperplasia Drugs Introduction
  • 12.2.4 Coloplast Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
  • 12.2.5 Coloplast Recent Development
• 12.3 Pfizer
  • 12.3.1 Pfizer Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Benign Prostate Hyperplasia Drugs Introduction
  • 12.3.4 Pfizer Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
  • 12.3.5 Pfizer Recent Development
• 12.4 Merck
  • 12.4.1 Merck Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Benign Prostate Hyperplasia Drugs Introduction
  • 12.4.4 Merck Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
  • 12.4.5 Merck Recent Development
• 12.5 GlaxoSmithKline
  • 12.5.1 GlaxoSmithKline Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Benign Prostate Hyperplasia Drugs Introduction
  • 12.5.4 GlaxoSmithKline Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
  • 12.5.5 GlaxoSmithKline Recent Development
• 12.6 Eli Lilly and Company
  • 12.6.1 Eli Lilly and Company Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Benign Prostate Hyperplasia Drugs Introduction
  • 12.6.4 Eli Lilly and Company Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
  • 12.6.5 Eli Lilly and Company Recent Development
• 12.7 Abbott Laboratories
  • 12.7.1 Abbott Laboratories Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Benign Prostate Hyperplasia Drugs Introduction
  • 12.7.4 Abbott Laboratories Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
  • 12.7.5 Abbott Laboratories Recent Development
• 12.8 Teva Pharmaceuticals
  • 12.8.1 Teva Pharmaceuticals Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Benign Prostate Hyperplasia Drugs Introduction
  • 12.8.4 Teva Pharmaceuticals Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
  • 12.8.5 Teva Pharmaceuticals Recent Development
• 12.9 Allergan
  • 12.9.1 Allergan Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Benign Prostate Hyperplasia Drugs Introduction
  • 12.9.4 Allergan Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
  • 12.9.5 Allergan Recent Development
• 12.10 Boehringer Ingelheim
  • 12.10.1 Boehringer Ingelheim Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Benign Prostate Hyperplasia Drugs Introduction
  • 12.10.4 Boehringer Ingelheim Revenue in Benign Prostate Hyperplasia Drugs Business (2014-2019)
  • 12.10.5 Boehringer Ingelheim Recent Development

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Product (2019-2025)
• 13.2 Market Size Forecast by Application (2019-2025)
• 13.3 Market Size Forecast by Regions
• 13.4 North America
• 13.5 Europe
• 13.6 China
• 13.7 Japan
• 13.8 Southeast Asia
• 13.9 India
• 13.10 Central & South America

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer